Clinical Trial Update: PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of the BTK inhibitor Ibrutinib (PCI-32765) in special cases of chronic lymphocytic leukemia and small lymphocytic lymphoma; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Leukemia, Leukemia, Lymphocytyc | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2018-07-11